News and Announcements
Imugene (AXS: IMU) Commences Phase 1b/2 Gastric Cancer Study, Receives Approvals to Initiate Clinical Trial & Secures Further Intellectual Property
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX: IMU), an immunoncology company is pleased to release its Appendix 4C for the quarter ended 30th June, 2017.
KEY TAKEAWAYS:
- Commenced the Phase 1b/2 gastric cancer study for HER-Vaxx
- Received full and final country regulatory approvals to initiate clinical trial;
- Commenced patient recruitment in all 8 clinical sites in Thailand, Taiwan and Hong Kong
- Secured further intellectual property for HER-Vaxx
- Completed further development of the next generation of mimotope targets and pipeline
- Commenced in vivo testing of arginine modulator in animal models of cancer
Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
